Fibroblast growth factor-2 (FGF2) and syndecan-1 (SDC1) as biomarkers for poor outcome Hodgkin lymphoma patients

摘要

The described invention comprises methods for predicting recurrence of Hodgkin Lymphoma (HL) and poor clinical outcome in a Hodgkin Lymphoma (HL) subject. The methods comprise providing a sample from the HL subject and a sample from a good clinical outcome control subject; isolating total RNA comprising Fibroblast Growth Factor-2 (FGF2) and Syndecan-1 (SDCI) RNA from the sample from the HL subject and from the sample from the good clinical outcome control subject; amplifying the total RNA; measuring a level of expression of the FGF2 and the SDCI RNA in the HL subject and in the good clinical outcome control subject; and comparing the level of expression of the FGF2 and the SDCI RNA expressed by the HL subject with the level of expression of the FGF2 and the SDCI RNA expressed by the good clinical outcome control subject.